Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (14849)	12/21/2004 2:16:37 PM
From: Michael Young	Read Replies (1) \| Respond to of 52153

Statins clearly reduce mortality, so the risk/reward equation is much different.

To: BulbaMan who wrote (14849)	12/21/2004 2:21:09 PM
From: Tomato	Respond to of 52153

I think there's a lot of stuff on the internet about statins and memory loss, but I have trouble remembering where exactly I saw it....;-) Statin User

To: BulbaMan who wrote (14849)	12/21/2004 8:43:15 PM
From: IRWIN JAMES FRANKEL	Read Replies (2) \| Respond to of 52153

>>My guess is the next class of drugs to get hit by safety concerns is the statins. Today I was in a meeting with a room full of MD's and Phd's. The conversation turned to the Vioxx/Celebrex/Naproxin situation. The general feeling was that medical professionals would not come to the defense of these pain killers. Someone then stated that the statins were risky mentioning rapto and other risks. It was like flipping a switch. Suddenly these same medical professionals started defending the statins and the drug companies. The risks of statins were justified by the benefits of the drugs. This reaction of informed medical professionals could not be more instructive. Statins are seen as essential to health care. Pain relief is optional. ij